1. Vanholder R, Argiles A, Baurmeister U, Brunet P, et al. Uremic toxicity: present state of the art. Int J Artif Organs 2001; 24: 695-725.
2. Eckardt KU, Berns JS, Rocco MV, Kasiske BL. Definition and classification of CKD:
the debate should be about patient prognosis--a position statement from KDOQI and KDIGO. Am J Kidney Dis 2009; 53: 915-920.
3. Locatelli F, Vecchio LD, Pozzoni P. The importance of early detection of chronic kid-ney disease. Nephrol Dial Transplant 2002; 17 Suppl 11: 2-7.
4. Kimura G. [Integrated care and expected outcomes over the progression of CKD (chronic kidney disease)]. Nippon Rinsho 2008; 66: 1807-1813.
5. Fogo AB. Progression and potential regression of glomerulosclerosis. Kidney Int 2001; 59: 804-819.
6. Krol E, Rutkowski B, Czarniak P, Kraszewska E, et al. Early detection of chronic kid-ney disease: results of the PolNef study. Am J Nephrol 2009; 29: 264-273.
7. Schölmerich J. Medizinische Therapie 3.ed. Springer Berlin Heidelberg, 2007/2008, 1000-1003pp.
8. Kramar R OR. Oesterreichisches Dialyse und Transplatationsregister ÖDTR. Jahres-bericht 2008 der Österreichischen Gesellschat für Nephrologie 2008.
9. Schmidt UF TJ, Mann U Der Internist. Glomerulonephritiden 2002; 43: 749-759.
10. Idasiak-Piechocka I, Krzymanski M. [The role of tubulointerstitial changes in progres-sion of kidney function failure in patients with chronic glomerulonephritis (GN)].
Przegl Lek 1996; 53: 443-453.
11. Ohashi R, Kitamura H, Yamanaka N. Peritubular capillary injury during the progres-sion of experimental glomerulonephritis in rats. J Am Soc Nephrol 2000; 11: 47-56.
12. Nakayama M, Sato T, Sato H, Yamaguchi Y, et al. Different clinical outcomes for cardiovascular events and mortality in chronic kidney disease according to underlying renal disease: the Gonryo study. Clin Exp Nephrol 2010; 14: 333-339.
13. Tepel M vdGM, Zidek W, . Praktische Therapie der chronischen Niereninsuffizienz durch Progressionshemmung. Dt Ärzteblatt 1997; 94: 2648-2652.
14. Gelber RP, Kurth T, Kausz AT, Manson JE, et al. Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis 2005; 46: 871-880.
15. Halimi JM, Mimran A. Renal effects of smoking: potential mechanisms and perspec-tives. Nephrol Dial Transplant 2000; 15: 938-940.
16. Briganti EM, Branley P, Chadban SJ, Shaw JE, et al. Smoking is associated with renal impairment and proteinuria in the normal population: the AusDiab kidney study. Aus-tralian Diabetes, Obesity and Lifestyle Study. Am J Kidney Dis 2002; 40: 704-712.
17. Fored CM, Ejerblad E, Lindblad P, Fryzek JP, et al. Acetaminophen, aspirin, and chronic renal failure. N Engl J Med 2001; 345: 1801-1808.
18. Schober-Halstenberg HJF, U. Nierenersatztherapie in Deutschland Quasi-Niere 2006-2007: 1-64.
19. John R, Webb M, Young A, Stevens PE. Unreferred chronic kidney disease: a longi-tudinal study. Am J Kidney Dis 2004; 43: 825-835.
20. Goodman WG, Goldin J, Kuizon BD, Yoon C, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483.
21. Vanholder R, Massy Z, Argiles A, Spasovski G, et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-1056.
22. Klag MJ, Whelton PK, Randall BL, Neaton JD, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13-18.
23. Tozawa M, Iseki K, Iseki C, Kinjo K, et al. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension 2003; 41: 1341-1345.
24. Ridao N, Luno J, Garcia de Vinuesa S, Gomez F, et al. Prevalence of hypertension in renal disease. Nephrol Dial Transplant 2001; 16 Suppl 1: 70-73.
25. Collins AJ, Li S, Gilbertson DT, Liu J, et al. Chronic kidney disease and cardiovascu-lar disease in the Medicare population. Kidney Int Suppl 2003: S24-31.
26. Foley RN, Murray AM, Li S, Herzog CA, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16: 489-495.
27. Caulfied M PJ, Dominiczak A, et al. The MRC British Genetics of Hypertension Stu-dy - Genome-wide screen results. Journal of Hypertension 2002; 20: 5-7.
28. Edwards NL. The role of hyperuricemia in vascular disorders. Curr Opin Rheumatol 2009; 21: 132-137.
29. David S, Kumpers P, Lukasz A, Kielstein JT, et al. Circulating angiopoietin-2 in es-sential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin. J Hypertens 2009; 27: 1641-1647.
30. Quack I, Rump LC. [Kidney and hypertension]. Internist (Berl) 2009; 50: 410-422.
31. Pruijm MBE, Burnier M. Arterielle Hypertonie und Niereninsuffizienz. Schweiz Med Forum 2009; 9: 497.
32. Hense HW. Risk factor scoring for coronary heart disease. BMJ 2003; 327: 1238-1239.
33. Moebus S, Hanisch JU, Lösch C, Bramlage P, et al. Arterial Hypertension and ab-dominal obsity are the most important factors of the metabolic syndrome in a cohort of 35,869 patients in primary care. J Hypertonsion 2008; 12: 7-11.
34. Deutschland G. Gesundheit in Deutschland, GBE. 2006.
35. Chobanian AV, Bakris GL, Black HR, Cushman WC, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Jama 2003; 289: 2560-2572.
36. Scinicariello F, Yesupriya A, Chang MH, Fowler BA. Modification by ALAD of the Association between Blood Lead and Blood Pressure in the U.S. Population: Results from the Third National Health and Nutrition Examination Survey. Environ Health Perspect 2010; 118: 259-264.
37. Lifton RP. Molecular genetics of human blood pressure variation. Science 1996; 272:
676-680.
38. Carretero OA, Oparil S. Essential hypertension. Part I: definition and etiology. Circu-lation 2000; 101: 329-335.
39. London GM. Cardiovascular disease in chronic renal failure: pathophysiologic as-pects. Semin Dial 2003; 16: 85-94.
40. Belov YV, Stepanenko AB, Gens AP, Radnaev Ch D, et al. Staged surgical treatment of vasorenal hypertension in the long-term period after repair of the thoracoabdominal aorta. Angiol Sosud Khir 2006; 12: 127-131.
41. Wofford MR, King DS, Wyatt SB, Jones DW. Secondary Hypertension: Detection and Management for the Primary Care Provider. J Clin Hypertens 2000; 2: 124-131.
42. K/DOQI. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-266.
43. Nitschke M, Meier M, Steinhoff J. [Acute and chronic renal insufficiency. Diagnostics and practical implications]. Med Klin (Munich) 2008; 103: 500-511; quiz 512-503.
44. Lemley KV. An introduction to biomarkers: applications to chronic kidney disease.
Pediatr Nephrol 2007; 22: 1849-1859.
45. Perco P, Pleban C, Kainz A, Lukas A, et al. Protein biomarkers associated with acute renal failure and chronic kidney disease. Eur J Clin Invest 2006; 36: 753-763.
46. Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of kidney disease. Scand J Clin Lab Invest Suppl 2008; 241: 89-94.
47. Kirkland JJ, Henderson JW, DeStefano JJ, van Straten MA, et al. Stability of silica-based, endcapped columns with pH 7 and 11 mobile phases for reversed-phase high-performance liquid chromatography. J Chromatogr A 1997; 762: 97-112.
48. Glajch JL, Kirkland JJ, Kohler J. Effect of column degradation on the reversed-phase high-performance liquid chromatographic separation of peptides and proteins. J Chromatogr 1987; 384: 81-90.
49. Jankowski V, Vanholder R, Henning L, Karadogan S, et al. Isolation and quantifica-tion of dinucleoside polyphosphates by using monolithic reversed phase chromatogra-phy columns. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 819: 131-139.
50. Meyer VR. Praxis der Hochleistungs-Flüssigchromatographie, 2009.
51. Hillenkamp F, Karas M, Beavis RC, Chait BT. Matrix-assisted Laser Desorp-tion/Ionization Mass spectrometry. Anal Chem 1991; 63: 1196A-1203A.
52. Nordhoff E, Ingendoh A, Cramer R, Overberg A, et al. Matrix-assisted laser desorp-tion/ionization mass spectrometry of nucleic acids with wavelengths in the ultraviolet and infrared. Rapid Commun Mass Spectrom 1992; 6: 771-776.
53. Suckau D, Resemann A, Schuerenberg M, Hufnagel P, et al. A novel MALDI LIFT-TOF/TOF mass spectrometer for proteomics. Anal Bioanal Chem 2003; 376: 952-965.
54. Mann M, Wilm M. Electrospray mass spectrometry for protein characterization.
Trends Biochem Sci 1995; 20: 219-224.
55. McCormack AL, Schieltz DM, Goode B, Yang S, et al. Direct analysis and identifica-tion of proteins in mixtures by LC/MS/MS and database searching at the low-femtomole level. Anal Chem 1997; 69: 767-776.
56. Marshall AG, Hendrickson CL, Jackson GS. Fourier transform ion cyclotron reso-nance mass spectrometry: a primer. Mass Spectrom Rev 1998; 17: 1-35.
57. Solouki T, Reinhold BB, Costello CE, O'Malley M, et al. Electrospray ionization and matrix-assisted laser desorption/ionization Fourier transform ion cyclotron resonance mass spectrometry of permethylated oligosaccharides. Anal Chem 1998; 70: 857-864.
58. Peach MJ. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol Rev 1977; 57: 313-370.
59. Campbell DJ. Circulating and tissue angiotensin systems. J Clin Invest 1987; 79: 1-6.
60. Dell'Italia LJ, Meng QC, Balcells E, Wei CC, et al. Compartmentalization of angio-tensin II generation in the dog heart. Evidence for independent mechanisms in in-travascular and interstitial spaces. J Clin Invest 1997; 100: 253-258.
61. Müller DN, Bohlender J, Hilgers KF, Dragun D, et al. Vascular angiotensin-converting enzyme expression regulates local angiotensin II. Hypertension 1997; 29:
98-104.
62. Wolf G. [The renin-angiotensin-aldosterone system -- more complex as previously thought]. Med Klin (Munich) 2005; 100: 471-477.
63. Dorer FE, Kahn JR, Lentz KE, Levine M, et al. Purification and properties of angio-tensin-converting enzyme from hog lung. Circ Res 1972; 31: 356-366.
64. Leung PS. The peptide hormone angiotensin II: its new functions in tissues and or-gans. Curr Protein Pept Sci 2004; 5: 267-273.
65. Zini S, Fournie-Zaluski MC, Chauvel E, Roques BP, et al. Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: pre-dominant role of angiotensin III in the control of vasopressin release. Proc Natl Acad Sci U S A 1996; 93: 11968-11973.
66. Rebas E, Lachowicz-Ochedalska A. The effect of angiotensin III on protein tyrosine kinase activity in rat pituitary. Regul Pept 2005; 130: 14-18.
67. Le MT, Vanderheyden PM, Szaszak M, Hunyady L, et al. Angiotensin IV is a potent agonist for constitutive active human AT1 receptors. Distinct roles of the N-and C-terminal residues of angiotensin II during AT1 receptor activation. J Biol Chem 2002;
277: 23107-23110.
68. de Gasparo M, Catt KJ, Inagami T, Wright JW, et al. International union of pharma-cology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-472.
69. Santos RA, Ferreira AJ, Simoes ESAC. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol 2008; 93: 519-527.
70. Santos RA, Campagnole-Santos MJ, Andrade SP. Angiotensin-(1-7): an update. Regul Pept 2000; 91: 45-62.
71. Jankowski V, Vanholder R, van der Giet M, Tolle M, et al. Mass-spectrometric identi-fication of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol 2007; 27: 297-302.
72. Gobom J, Schuerenberg M, Mueller M, Theiss D, et al. Alpha-cyano-4-hydroxycinnamic acid affinity sample preparation. A protocol for MALDI-MS peptide analysis in proteomics. Anal Chem 2001; 73: 434-438.
73. Jankowski V, Vanholder R, van der Giet M, Henning L, et al. Detection of angio-tensin II in supernatants of stimulated mononuclear leukocytes by matrix-assisted laser desorption ionization time-of-flight/time-of-flight mass analysis. Hypertension 2005;
46: 591-597.
74. Orzechowski HD, Gunther A, Menzel S, Zimmermann A, et al. Transcriptional me-chanism of protein kinase C-induced isoform-specific expression of the gene for endo-thelin-converting enzyme-1 in human endothelial cells. Mol Pharmacol 2001; 60:
1332-1342.
75. Beyermann M, Fechner K, Furkert J, Krause E, et al. A single-point slight alteration set as a tool for structure-activity relationship studies of ovine corticotropin releasing factor. J Med Chem 1996; 39: 3324-3330.
76. Douglas SA, Sulpizio AC, Piercy V, Sarau HM, et al. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 2000; 131: 1262-1274.
77. Pesquero JB, Lindsey CJ, Zeh K, Paiva AC, et al. Molecular structure and expression of rat bradykinin B2 receptor gene. Evidence for alternative splicing. J Biol Chem 1994; 269: 26920-26925.
78. Young D, Waitches G, Birchmeier C, Fasano O, et al. Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains. Cell 1986; 45: 711-719.
79. Jackson TR, Blair LA, Marshall J, Goedert M, et al. The mas oncogene encodes an angiotensin receptor. Nature 1988; 335: 437-440.
80. Ambroz C, Clark AJ, Catt KJ. The mas oncogene enhances angiotensin-induced [Ca2+]i responses in cells with pre-existing angiotensin II receptors. Biochim Biophys Acta 1991; 1133: 107-111.
81. Ardaillou R. Angiotensin II receptors. J Am Soc Nephrol 1999; 10 Suppl 11: S30-39.
82. Walther T, Balschun D, Voigt JP, Fink H, et al. Sustained long term potentiation and anxiety in mice lacking the Mas protooncogene. J Biol Chem 1998; 273: 11867-11873.
83. Santos RA, Simoes e Silva AC, Maric C, Silva DM, et al. Angiotensin-(1-7) is an en-dogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 2003; 100: 8258-8263.
84. Tallant EA, Ferrario CM, Gallagher PE. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol 2005; 289: H1560-1566.
85. Sampaio WO, Henrique de Castro C, Santos RA, Schiffrin EL, et al. Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension 2007; 50: 1093-1098.
86. Lüthje J, Ogilvie A. The presence of diadenosine 5',5'''-P1,P3-triphosphate (Ap3A) in human platelets. Biochem Biophys Res Commun 1983; 115: 253-260.
87. Schlüter H, Tepel M, Zidek W. Vascular actions of diadenosine phosphates. J Auton Pharmacol 1996; 16: 357-362.
88. Jankowski J, Tepel M, van der Giet M, Tente IM, et al. Identification and characteri-zation of P(1), P(7)-Di(adenosine-5')- heptaphosphate from human platelets. J Biol Chem 1999; 274: 23926-23931.
89. Jankowski J, Hagemann J, Yoon MS, Van Der Giet M, et al. Increased vascular growth in hemodialysis patients induced by platelet- derived diadenosine polyphos-phates. Kidney Int 2001; 59: 1134-1141.
90. Luo J, Jankowski J, Tepel M, von der Giet M, et al. Identification of diadenosine he-xaphosphate in human erythrocytes. Hypertension 1999; 34: 872-875.
91. Luo J, Jankowski J, Knobloch M, van der Giet M, et al. Identification and characteri-zation of diadenosine 5',5"'-P1,P2 - diphosphate and diadenosine 5',5"'-P1,P3-triphosphate in human myocardial tissue. Faseb J 1999; 13: 695-705.
92. Jankowski J, Yoon MS, Stephan N, Zidek W, et al. Vasoactive diadenosine polyphos-phates in human placenta: possible candidates in the pathophysiology of pre-eclampsia? J Hypertens 2001; 19: 567-573.
93. Jankowski V, Tolle M, Vanholder R, Schonfelder G, et al. Uridine adenosine tetra-phosphate: a novel endothelium- derived vasoconstrictive factor. Nat Med 2005; 11:
223-227.
94. Jankowski V, van der Giet M, Mischak H, Morgan M, et al. Dinucleoside polyphos-phates: strong endogenous agonists of the purinergic system. Br J Pharmacol 2009.
95. Wang L, Karlsson L, Moses S, Hultgardh-Nilsson A, et al. P2 receptor expression profiles in human vascular smooth muscle and endothelial cells. J Cardiovasc Phar-macol 2002; 40: 841-853.
96. Bobbert P, Schluter H, Schultheiss HP, Reusch HP. Diadenosine polyphosphates Ap3A and Ap4A, but not Ap5A or Ap6A, induce proliferation of vascular smooth muscle cells. Biochem Pharmacol 2008; 75: 1966-1973.
97. Vonend O, Grote T, Oberhauser V, Von Kugelgen I, et al. P2Y-receptors stimulating the proliferation of human mesangial cells through the MAPK42/44 pathway. Br J Pharmacol 2003; 139: 1119-1126.
98. Lu M, MacGregor GG, Wang W, Giebisch G. Extracellular ATP inhibits the small-conductance K channel on the apical membrane of the cortical collecting duct from mouse kidney. J Gen Physiol 2000; 116: 299-310.
99. Turner CM, Vonend O, Chan C, Burnstock G, et al. The pattern of distribution of se-lected ATP-sensitive P2 receptor subtypes in normal rat kidney: an immunohistologi-cal study. Cells Tissues Organs 2003; 175: 105-117.
100. Muller AM, Gruhn K, Lange S, Franke FE, et al. [Angiotensin converting enzyme (ACE, CD143) in the regular pulmonary vasculature]. Pathologe 2004; 25: 141-146.
101. Siegenthaler W BHE. Klinische Pathophysiologie. 2006: 665.
102. Jankowski V TM, van der Giet M, Zidek W, Jankowski J, . Angioprotektin: An Ang-like peptide causing vasodilatory effects. JCI 2010.
103. Jankowski V, Patzak A, Herget-Rosenthal S, Tran TN, et al. Uridine adenosine tetra-phosphate acts as an autocrine hormone affecting glomerular filtration rate. J Mol Med 2008; 86: 333-340.
104. Jankowski V, Meyer AA, Schlattmann P, Gui Y, et al. Increased uridine adenosine tetraphosphate concentrations in plasma of juvenile hypertensives. Arterioscler Thromb Vasc Biol 2007; 27: 1776-1781.
105. Yegutkin GG, Samburski SS, Jalkanen S. Soluble purine-converting enzymes circulate in human blood and regulate extracellular ATP level via counteracting pyrophos-phatase and phosphotransfer reactions. FASEB J 2003; 17: 1328-1330.
106. Yegutkin GG, Samburski SS, Mortensen SP, Jalkanen S, et al. Intravascular ADP and soluble nucleotidases contribute to acute prothrombotic state during vigorous exercise in humans. J Physiol 2007; 579: 553-564.
107. Birk AV, Bubman D, Broekman MJ, Robertson HD, et al. Role of a novel soluble nucleotide phospho-hydrolase from sheep plasma in inhibition of platelet reactivity:
hemostasis, thrombosis, and vascular biology. J Lab Clin Med 2002; 139: 116-124.
108. Delicado EG, Miras-Portugal MT, Carrasquero LM, Leon D, et al. Dinucleoside poly-phosphates and their interaction with other nucleotide signaling pathways. Pflugers Arch 2006; 452: 563-572.
109. Yang G, Yu X, Wu Z, Xu J, et al. Molecular cloning and characterization of a novel adenylate kinase 3 gene from Clonorchis sinensis. Parasitol Res 2005; 95: 406-412.